Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRON TAVI trial of ferric carboxymaltose in iron-deficient patients undergoing TAVI
NL-OMON59789Phase 4Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ferric carboxymaltose in iron deficiency anemia (IDA) and aortic stenosis (AS), sponsored by Erasmus MC. Primary endpoints: Quality of life at 6 months and Exercise capacity at 6 months. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)aortic stenosis (AS)
Beyond the preview
Go deeper on NL-OMON59789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59789.